IGFBP7
Reactivity: Human
WB, ELISA
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Peptide ELISA: Limit Dilution: 1/8000. Western blot: 1-3 μg/mL. Approx 30 kDa band observed in Mouse Kidney lysates (calculatedMW of 29.0 kDa according to Human NP_001544.1 and to Mouse NP_032074.3). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0.5 mg/mL
Buffer
Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
IGFBP7
(Insulin-Like Growth Factor Binding Protein 7 (IGFBP7))
IGF-BPs form high affinity complexes with both IGF-I and IGF-II and act to control of the distribution, function and activity of IGFs in various cell tissues and body fluids. There are seven named IGF-BPs. IGFBP7 plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGFBP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. IGFBP7 is expressed in a wide range of normal human tissues and it usually shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.Synonyms: IBP-7, IBP7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, Insulin-like growth factor-binding protein 7, MAC25, PGI2-stimulating factor, PSF, Prostacyclin-stimulating factor, TAF, Tumor-derived adhesion factor